These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

325 related items for PubMed ID: 17439686

  • 1. Treatment outcome cohort analysis in an integrated DOTS and DOTS-Plus TB program in Latvia.
    Riekstina V, Leimane V, Holtz TH, Leimans J, Wells CD.
    Int J Tuberc Lung Dis; 2007 May; 11(5):585-7. PubMed ID: 17439686
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Prevalence of drug resistance under the DOTS strategy in Hyderabad, South India, 2001-2003.
    Anuradha B, Aparna S, Hari Sai Priya V, Vijaya Lakshmi V, Akbar Y, Suman Latha G, Murthy KJ.
    Int J Tuberc Lung Dis; 2006 Jan; 10(1):58-62. PubMed ID: 16466038
    [Abstract] [Full Text] [Related]

  • 6. Outcomes of individualised treatment for multidrug-resistant tuberculosis before DOTS-plus.
    Ollé-Goig JE, Sandy R.
    Int J Tuberc Lung Dis; 2005 Jul; 9(7):765-70. PubMed ID: 16013772
    [Abstract] [Full Text] [Related]

  • 7. Results of a standardised regimen for multidrug-resistant tuberculosis in Bangladesh.
    Van Deun A, Salim MA, Das AP, Bastian I, Portaels F.
    Int J Tuberc Lung Dis; 2004 May; 8(5):560-7. PubMed ID: 15137531
    [Abstract] [Full Text] [Related]

  • 8. Tuberculosis drug resistance and treatment outcomes under DOTS settings in large cities in the Philippines.
    Ohkado A, Aguiman L, Adlawan S, Baring E, Quirante O, Suchi M, Endo S, Fujiki A, Mori T.
    Int J Tuberc Lung Dis; 2006 Mar; 10(3):283-9. PubMed ID: 16562708
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Evaluation of effect of community DOTS on treatment outcomes by TB surveillance data].
    Hoshino H, Kobayashi N.
    Kekkaku; 2006 Oct; 81(10):591-602. PubMed ID: 17094581
    [Abstract] [Full Text] [Related]

  • 15. Adverse events related to multidrug-resistant tuberculosis treatment, Latvia, 2000-2004.
    Bloss E, Kuksa L, Holtz TH, Riekstina V, Skripconoka V, Kammerer S, Leimane V.
    Int J Tuberc Lung Dis; 2010 Mar; 14(3):275-81. PubMed ID: 20132617
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Study on the efficacy and safety of short-term treatment including fluoroquinolones anti-tuberculosis drugs for rifampicin resistant pulmonary tuberculosis].
    Kang WL, Xie YG, Tan WG, Chu NH, Li L, You YH, Yang YZ, Wang XM, Yan XL, Miao ZP, Duanmu HJ.
    Zhonghua Liu Xing Bing Xue Za Zhi; 2009 Feb; 30(2):179-83. PubMed ID: 19565883
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.